Activation of CISD2 as a protective strategy against doxorubicin-induced cardiotoxicity.

ABSTRACT:

Background

Cardiotoxicity of doxorubicin, a chemotherapy medication, remains the most dangerous side effect. CISD2 plays a critical role during cardiac aging.

Objectives

We use a potent CISD2 activator, hesperetin, to ameliorate doxorubicin-induced cardiotoxicity by upregulating CISD2 in mice.

Methods

Two animal models, an acute and a tumor-bearing doxorubicin-induced cardiotoxicity model, were used in this study. Both genetic and pharmacological approaches were employed. Transgenic mice and a potent CISD2 activator, hesperetin, were utilized to ameliorate doxorubicin-induced cardiotoxicity by upregulating CISD2 expression in mice. Additionally, a human-derived iPSC system was used to provide human-relevant evidence. Comprehensive biological, histological, transcripto

SUBMITTER: Chou YJ 

PROVIDER: S-EPMC12409322 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature